Atomo Diagnostics released its quarterly activity report yesterday, which included a mammoth boost in cash receipts. We take a closer look at what the company has been up to.
The post Atomo Diagnostics (ASX:AT1) posts 709% boost in quarterly cash receipts appeared first on The Motley Fool Australia. –
The Atomo Diagnostics Ltd (ASX:AT1) share price dipped yesterday and has remained flat today after the medical device company released its quarterly activity report for the period ended 31 December 2020.
Atomo designs blood-based rapid diagnostic test (RDT) devices. Through the company’s device portfolio, it aims to provide technology that simplifies the blood testing process and reduces errors. The company offers options for both medical professionals as well as for people who require self-testing to manage their health.
Quarterly activity report highlights
According to yesterday’s quarterly activity report, the company brought in a total of $5.8 million in cash receipts for the first half of the FY21. This includes $2.8 million gained during the second quarter, up a whopping 709% from $346,000 in the previous corresponding period.
Sales for the second quarter of FY21 (unaudited) came in around $2.0 million. The company also advised that an additional 259,200 units shipped to one of its US-based customers, Access Bio, aren’t reflected in revenue to date but will be booked as revenue in the third quarter FY21.
Across North America, Europe and Australia, Atomo continues to progress its rapid testing coronavirus technology. This involves activities like pursuing sales opportunities, finalising submissions and gaining associated approvals.
Additionally, the company continues to progress supply agreements pertaining to its HIV tests. New business is expected in the emerging global health market moving forward.
Positioning for growth
According to Atomo’s co-founder and managing director John Kelly, the company is positioning itself for growth. Mr Kelly believes that the current need for coronavirus tests around the world presents significant opportunity for Atomo.
During the quarter, Atomo launched its TGA-approved AtomoRapid COVID-19 antibody test for sale in the Australian market. Total sales for the product were $394,000 across a range of professional testing and corporate channels.
Mr Kelly goes on to note the Biden administration’s recent $50 billion commitment to fund testing across the US. As a result of this, Mr Kelly expects the coronavirus will continue to play an important part of Atomo’s business “for a number of years”.
Atomo share price snapshot
At the time of writing, the Atomo share price is sitting at 29.5 cents per share, giving the company a current market capitalisation of $166.4 million. The Atomo share price has stayed relatively flat in 2021 so far, and is down 24.36% on this time last year.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- Lotus Resources (ASX:LOT) share price tumbles 7% today but is still up 170% in a year
- Are InvoCare (ASX:IVC) shares the ASX version of GameStop?
- Why the MoneyMe (ASX:MME) share price is climbing higher
- Why Bigtincan, Bubs, LiveTiles, & Treasury Wine shares are storming higher
- Up 400% in 2021, why the Hawkstone (ASX:HWK) share price is rocketing 28% higher
Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.